<DOC>
	<DOCNO>NCT00254189</DOCNO>
	<brief_summary>To determine ability monophasic oral contraceptive ( `` OC '' ) regimen Levonorgestrel ( `` LNG '' ) 90 mg Ethinyl Estradiol ( `` EE '' ) 20 mg inhibit ovulation 84 day continuous therapy .</brief_summary>
	<brief_title>Study Evaluating Effects Levonorgestrel Ethinyl Estradiol Ovulation</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Healthy woman legal age consent willing use combination OC . Subjects must age 36 time enrollment ( visit 3 ) . Subjects must regular ( 24 32 day ) menstrual cycle 3month period precede entry pretreatment observation cycle , exclude postabortal nonnursing postpartum subject . Postabortal nonnursing postpartum subject must complete least 1 regular ( 24 32 day ) spontaneous menstrual cycle entry pretreatment observation cycle . The pretreatment observation cycle subject begin day 1 subsequent spontaneous menses . Other inclusion apply . A history presence follow prevent enrollment : Thrombophlebitis , thrombosis , thromboembolic disorder . Deep vein thrombosis . Pulmonary embolism . Other exclusion apply .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Ovulation</keyword>
	<keyword>Oral Contraceptive</keyword>
</DOC>